ClinicalTrials.gg
CompletedNCT03132636Updated Apr 8, 2025Results posted

PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

A Phase 2 interventional study of cemiplimab in Carcinoma, Basal Cell, sponsored by Regeneron Pharmaceuticals. Completed at 71 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-08.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
138
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 171 studies in Carcinoma, Basal Cell with a site in United States — 23 open to participants now, 38 under way, 2 of them phase 3. Carcinoma, Basal Cell · United States.

Enrollment
26th of 139
138 · median 40
Started
2017
with 5 others
Phase 2
46 of 171
6 open now
Registered
90th of 171
by date
Lead sponsor
4 of 171
Regeneron Pharmaceuticals

Among the 171 studies in Carcinoma, Basal Cell with a site in United States, this one is the 26th largest by enrollment of the 139 interventional ones that give a count, is one of 6 that started in 2017, is one of 46 in phase 2, and was the 90th registered.

Carcinoma, Basal Cell

389 studies on the registry are indexed under Carcinoma, Basal Cell; 69 are open to participants now.

Browse Carcinoma, Basal Cell studies →

Open to participants now

23 of the 171 studies in Carcinoma, Basal Cell with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 52 Carcinoma, Basal Cell studies recruiting now, 48 (92%) set no upper age limit and none (0%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 171 studies in Carcinoma, Basal Cell with a site in United States, or all of them as a file.
02

Study summary

The primary objective is to estimate the objective response rate (ORR) for metastatic Basal Cell Carcinoma (BCC) (group 1) and for unresectable locally advanced BCC (group 2) when treated with cemiplimab as a monotherapy

03

Conditions studied

  • Carcinoma, Basal Cell

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Confirmed diagnosis of invasive BCC
  • Progression of disease on hedgehog inhibitor (HHI) therapy or intolerance of prior HHI therapy
  • At least 1
  • ≥18 years of age
  • Hepatic function, renal function, bone marrow function in defined lab-value-ranges
  • Anticipated >12 weeks
  • Consent to provide archived tumor material (all patients)
  • Group 2: consent to undergo research biopsies
  • Group 2: must not be a candidate for radiation therapy or surgery
  • Comply with study procedures and site visits
  • Sign Subject Information Sheet and Form

Key Exclusion Criteria:

  • Ongoing or recent significant disease
  • Prior treatment with specific pathway-blockers (/PD-L1)
  • Prior treatment with immune-modulating agents within 28 days before cemiplimab
  • Untreated that may be considered active
  • doses (>10mg prednisone) within 28 days prior to treatment with cemiplimab
  • Active infections requiring therapy, including , hepatitis
  • Pneumonitis within the last 5 years
  • Cancer treatment other than radiation therapy, including or standard of care, within 30 days prior to treatment with cemiplimab
  • Documented allergic reactions or similar to antibody treatments
  • Concurrent other than BCC, other than those with negligible risk of or death
  • Any acute or chronic psychiatric problems
  • Having received a solid organ transplantation
  • Inability to undergo contrast radiological assessments
  • Breastfeeding, pregnant, women of not using

Note: Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
138 participants (actual)

Study arms

  • Experimental
    Group 1- metastatic BCC

    Administration of cemiplimab in accordance with protocol dosing regimen

    Drug: cemiplimab

  • Experimental
    Group 2 - unresectable locally advanced BCC

    Administration of cemiplimab in accordance with protocol dosing regimen

    Drug: cemiplimab

Interventions

  • Regimen as per protocol

    Also known as: REGN2810, Libtayo

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) as Assessed by Independent Central Review (ICR)

    ORR was defined as percentage of participants with best overall response of complete response (CR) or partial response (PR) according to RECIST v1.1 assessed as per ICR assessment. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeter (mm) (\< 1 centimeter \[cm\]). PR: At least a 30 percent (%) decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. ORR was determined by Clopper-Pearson method.

    Time frame: Up to 1422 days (approximately 46 months)

Secondary outcomes

  1. Objective Response Rate (ORR) Per Investigator Assessment

    ORR was defined as percentage of participants with best overall response of complete response (CR) or partial response (PR) according to RECIST v1.1 per Investigator assessment. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeter (mm) (\< 1 centimeter \[cm\]). PR: At least a 30 percent (%) decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. ORR was determined by Clopper-Pearson method.

    Time frame: Up to 1422 days (approximately 46 months)

  2. Duration of Response (DOR) as Assessed by ICR

    DOR per ICR was determined for participants with best overall response of CR or PR. DOR was measured from the time measurement criteria are first met for CR/PR (whichever was first recorded) until the first date of recurrent or progressive disease (PD) (photographic or radiographic), or death due to any cause. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm (\<1 cm). PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. PD: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). DOR was determined by Kaplan-Meier estimate.

    Time frame: Up to 48 months

  3. Duration of Response (DOR) Per Investigator Assessment

    DOR per investigator assessment was determined for participants with best overall response of CR or PR. DOR was measured from the time measurement criteria are first met for CR/PR (whichever was first recorded) until the first date of recurrent or progressive disease (PD) (photographic or radiographic), or death due to any cause. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm (\<1 cm). PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. PD: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). DOR was determined by Kaplan-Meier estimate.

    Time frame: Up to 48 months

  4. Complete Response (CR) Rate as Assessed by ICR

    CR rate was determined by the percentage of participants with best overall response of CR. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm (\<1 cm). CR rate 95% confidence interval determined by Clopper-Pearson exact confidence interval.

    Time frame: Up to 48 months

  5. Complete Response (CR) Rate Per Investigator Assessment

    CR rate was determined by the percentage of participants with best overall response of CR. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm (\<1 cm). CR rate 95% confidence interval determined by Clopper-Pearson exact confidence interval.

    Time frame: Up to 48 months

  6. Progression Free Survival (PFS) as Assessed by ICR

    PFS was defined as the time from start of treatment until the first date of recurrent or PD (photographic or radiographic), or death due to any cause, whichever occurred first, was determined by IRC. PD: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). PFS was determined by Kaplan-Meier estimate.

    Time frame: Up to 60 months

  7. Progression Free Survival (PFS) Per Investigator Assessment

    PFS was defined as the time from start of treatment until the first date of recurrent or PD (photographic or radiographic), or death due to any cause, whichever occurred first, was determined by IRC. PD: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). PFS was determined by Kaplan-Meier estimate.

    Time frame: Up to 60 months

  8. Overall Survival (OS)

    OS was measured as time from the start of treatment until death due to any cause. Participants who did not die were censored at the last date that participant was documented to be alive. OS was calculated based on Kaplan-Meier estimate.

    Time frame: Up to 60 months

  9. Change From Baseline of Patient-reported Outcomes in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)

    The EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall QoL in cancer participants. It consists of 15 domains: 1 Global Health Status (GHS)/QoL scale, 5 functional scales (Physical, role, cognitive, emotional, social), 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact). Most items are scored 1 ("not at all") to 4 ("very much") except for the items contributing to the GHS/QoL, which are scored 1 ("very poor") to 7 ("excellent"). A linear transformation was applied to the raw scores so that all transformed scores lie between 0 to 100. For the GHS/QoL and 5 functional scales a higher score indicates higher ("better") quality of life/functioning and a positive change from baseline indicates improvement. For the symptom scales/items, a higher score indicates a higher ("worse") level of symptoms/problems, and a negative change from baseline indicates improvement.

    Time frame: Baseline (Day 1 of Cycle 1); Day 1 of Cycles 2 to 9 (Cycles 1-5 [Each cycle of 9 weeks], Cycles 6 to 9 [Each cycle of 12 weeks])

  10. Change From Baseline of Patient-reported Outcomes in Skindex-16 Questionnaire

    Skindex-16 questionnaire contains 16 questions related to quality of life in cancer participants. It consisted of a short 16-item assessment completed by the participant, with each item rated on a 7-point Likert scale (0=never bothered to 6=always bothered). Each raw score is multiplied by 16.667 to transform all responses to a linear scale from 0 (no effect) to 100 (effect experienced all the time). Responses to the Skindex-16 are categorized into 3 subscales: symptom, emotional \& functional; their respective scores are expressed in a linear scale from 0 to 100. Symptoms scale score was an average of items 1 to 4 expressed in a linear scale from 0 to 100, Emotions scale score was an average of items 5 to 11 expressed in a linear scale from 0 to 100 and Functioning scale score was an average of items 12 to 16 expressed in a linear scale from 0 to 100. A negative change from baseline indicates an improvement in the participants condition compared to the baseline.

    Time frame: Baseline (Day 1 of Cycle 1); Day 1 of Cycles 2 to 9 (Cycles 1-5 [Each cycle of 9 weeks], Cycles 6 to 9 [Each cycle of 12 weeks])

  11. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs

    An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. TEAEs are defined as AEs that developed or worsened during the on-treatment period and treatment-related AEs that occur during post-treatment period. A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious TEAEs.

    Time frame: Up to 1422 days (approximately 46 months)

  12. Serum Concentration at Pre-infusion (Ctrough)

    Ctrough of cemiplimab reported.

    Time frame: At pre-infusion on Cycle 1 Day 22 and Cycle 3 Day 1 (Each cycle of 9 weeks)

  13. Serum Concentration at End of Infusion (Cmax)

    Cmax of cemiplimab was reported.

    Time frame: At end-of-infusion (within 10 minutes after the end of infusion) on Cycle 1 Day 1 and Cycle 3 Day 1 (Each cycle of 9 weeks)

  14. Number of Participants With Anti-Drug Antibody (ADA) Status

    Immunogenicity was characterized by ADA responses \& titers. Responses categories: Negative - ADA negative response at all time points, regardless of missing samples; Pre-existing immunoreactivity - ADA positive response at baseline with all post first dose negative results or positive response at baseline with all post first dose ADA responses \< 9-fold over baseline titer levels; Treatment-boosted response - positive response in the assay post first dose, ≥ 9-fold over baseline titer levels, when baseline results are positive; Treatment-emergent response - ADA positive response in the cemiplimab ADA assay post first dose when baseline results = negative or missing.

    Time frame: Cycle 1: Days 1 and 43; Cycles 3 and 5: Day 1 (Each cycle of 9 weeks)

07

Results

Posted Jul 26, 2022

Participant flow

Participant flow — Overall Study
MilestoneGroup 1: Metastatic BCC (mBCC)Group 2: Unresectable Locally Advanced BCC (laBCC)
Started5484
Completed treatment1128
Completed619
Not completed4865
Withdrew: Adverse event12
Withdrew: Death47
Withdrew: Lost to follow-up32
Withdrew: Non compliance with protocol by participant11
Withdrew: Subject decision19
Withdrew: Sponsor decision01
Withdrew: Physician decision10
Withdrew: Progressive disease3336
Withdrew: Withdrawal of consent25
Withdrew: Did not re-consent10
Withdrew: Lost insurance coverage10
Withdrew: Related to radiological outcomes01
Withdrew: Unable to come to site for continued visits01

Outcome measures

PrimaryObjective Response Rate (ORR) as Assessed by Independent Central Review (ICR)

ORR was defined as percentage of participants with best overall response of complete response (CR) or partial response (PR) according to RECIST v1.1 assessed as per ICR assessment. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeter (mm) (\< 1 centimeter \[cm\]). PR: At least a 30 percent (%) decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. ORR was determined by Clopper-Pearson method.

Time frame:
Up to 1422 days (approximately 46 months)
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) as Assessed by Independent Central Review (ICR)
Percentage of ParticipantsGroup 1: Metastatic BCC (mBCC)Group 2: Unresectable Locally Advanced BCC (laBCC)
Objective Response Rate (ORR) as Assessed by Independent Central Review (ICR)22.2 (12.0 to 35.6)32.1 (22.4 to 43.2)
SecondaryObjective Response Rate (ORR) Per Investigator Assessment

ORR was defined as percentage of participants with best overall response of complete response (CR) or partial response (PR) according to RECIST v1.1 per Investigator assessment. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeter (mm) (\< 1 centimeter \[cm\]). PR: At least a 30 percent (%) decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. ORR was determined by Clopper-Pearson method.

Time frame:
Up to 1422 days (approximately 46 months)
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) Per Investigator Assessment
Percentage of ParticipantsGroup 1: Metastatic BCC (mBCC)Group 2: Unresectable Locally Advanced BCC (laBCC)
Objective Response Rate (ORR) Per Investigator Assessment25.9 (15.0 to 39.7)36.9 (26.6 to 48.1)
SecondaryDuration of Response (DOR) as Assessed by ICR

DOR per ICR was determined for participants with best overall response of CR or PR. DOR was measured from the time measurement criteria are first met for CR/PR (whichever was first recorded) until the first date of recurrent or progressive disease (PD) (photographic or radiographic), or death due to any cause. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm (\<1 cm). PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. PD: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). DOR was determined by Kaplan-Meier estimate.

Time frame:
Up to 48 months
Reported as:
Median · Months
Duration of Response (DOR) as Assessed by ICR
MonthsGroup 1: Metastatic BCC (mBCC)Group 2: Unresectable Locally Advanced BCC (laBCC)
Duration of Response (DOR) as Assessed by ICRNA (9.8 to NA)NA (15.5 to NA)
SecondaryDuration of Response (DOR) Per Investigator Assessment

DOR per investigator assessment was determined for participants with best overall response of CR or PR. DOR was measured from the time measurement criteria are first met for CR/PR (whichever was first recorded) until the first date of recurrent or progressive disease (PD) (photographic or radiographic), or death due to any cause. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm (\<1 cm). PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. PD: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). DOR was determined by Kaplan-Meier estimate.

Time frame:
Up to 48 months
Reported as:
Median · Months
Duration of Response (DOR) Per Investigator Assessment
MonthsGroup 1: Metastatic BCC (mBCC)Group 2: Unresectable Locally Advanced BCC (laBCC)
Duration of Response (DOR) Per Investigator AssessmentNA (9.8 to NA)19.6 (16.7 to NA)
SecondaryComplete Response (CR) Rate as Assessed by ICR

CR rate was determined by the percentage of participants with best overall response of CR. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm (\<1 cm). CR rate 95% confidence interval determined by Clopper-Pearson exact confidence interval.

Time frame:
Up to 48 months
Reported as:
Number · Percentage of Participants
Complete Response (CR) Rate as Assessed by ICR
Percentage of ParticipantsGroup 1: Metastatic BCC (mBCC)Group 2: Unresectable Locally Advanced BCC (laBCC)
Complete Response (CR) Rate as Assessed by ICR3.7 (0.5 to 12.7)8.3 (3.4 to 16.4)
SecondaryComplete Response (CR) Rate Per Investigator Assessment

CR rate was determined by the percentage of participants with best overall response of CR. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm (\<1 cm). CR rate 95% confidence interval determined by Clopper-Pearson exact confidence interval.

Time frame:
Up to 48 months
Reported as:
Number · Percentage of Participants
Complete Response (CR) Rate Per Investigator Assessment
Percentage of ParticipantsGroup 1: Metastatic BCC (mBCC)Group 2: Unresectable Locally Advanced BCC (laBCC)
Complete Response (CR) Rate Per Investigator Assessment3.7 (0.5 to 12.7)8.3 (3.4 to 16.4)
SecondaryProgression Free Survival (PFS) as Assessed by ICR

PFS was defined as the time from start of treatment until the first date of recurrent or PD (photographic or radiographic), or death due to any cause, whichever occurred first, was determined by IRC. PD: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). PFS was determined by Kaplan-Meier estimate.

Time frame:
Up to 60 months
Reported as:
Median · Months
Progression Free Survival (PFS) as Assessed by ICR
MonthsGroup 1: Metastatic BCC (mBCC)Group 2: Unresectable Locally Advanced BCC (laBCC)
Progression Free Survival (PFS) as Assessed by ICR10.1 (4.2 to 15.9)16.5 (8.6 to 21.8)
SecondaryProgression Free Survival (PFS) Per Investigator Assessment

PFS was defined as the time from start of treatment until the first date of recurrent or PD (photographic or radiographic), or death due to any cause, whichever occurred first, was determined by IRC. PD: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). PFS was determined by Kaplan-Meier estimate.

Time frame:
Up to 60 months
Reported as:
Median · Months
Progression Free Survival (PFS) Per Investigator Assessment
MonthsGroup 1: Metastatic BCC (mBCC)Group 2: Unresectable Locally Advanced BCC (laBCC)
Progression Free Survival (PFS) Per Investigator Assessment6.6 (4.2 to 8.3)18.1 (10.4 to 21.3)
SecondaryOverall Survival (OS)

OS was measured as time from the start of treatment until death due to any cause. Participants who did not die were censored at the last date that participant was documented to be alive. OS was calculated based on Kaplan-Meier estimate.

Time frame:
Up to 60 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsGroup 1: Metastatic BCC (mBCC)Group 2: Unresectable Locally Advanced BCC (laBCC)
Overall Survival (OS)49.9 (28.4 to NA)NA (NA to NA)
SecondaryChange From Baseline of Patient-reported Outcomes in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)

The EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall QoL in cancer participants. It consists of 15 domains: 1 Global Health Status (GHS)/QoL scale, 5 functional scales (Physical, role, cognitive, emotional, social), 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact). Most items are scored 1 ("not at all") to 4 ("very much") except for the items contributing to the GHS/QoL, which are scored 1 ("very poor") to 7 ("excellent"). A linear transformation was applied to the raw scores so that all transformed scores lie between 0 to 100. For the GHS/QoL and 5 functional scales a higher score indicates higher ("better") quality of life/functioning and a positive change from baseline indicates improvement. For the symptom scales/items, a higher score indicates a higher ("worse") level of symptoms/problems, and a negative change from baseline indicates improvement.

Time frame:
Baseline (Day 1 of Cycle 1); Day 1 of Cycles 2 to 9 (Cycles 1-5 [Each cycle of 9 weeks], Cycles 6 to 9 [Each cycle of 12 weeks])
Reported as:
Mean · Score on a Scale
Change From Baseline of Patient-reported Outcomes in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
Score on a ScaleGroup 1: Metastatic BCC (mBCC)Group 2: Unresectable Locally Advanced BCC (laBCC)
Physical Functioning: Change at Cycle 2 Day 1-4.88 ± 14.274-1.55 ± 12.101
Physical Functioning: Change at Cycle 3 Day 1-1.78 ± 13.481-0.56 ± 15.947
Physical Functioning: Change at Cycle 4 Day 1-6.60 ± 12.828-3.79 ± 17.814
Physical Functioning: Change at Cycle 5 Day 11.08 ± 10.033-2.86 ± 17.063
Physical Functioning: Change at Cycle 6 Day 1-1.67 ± 9.7340.33 ± 12.073
Physical Functioning: Change at Cycle 7 Day 1-0.38 ± 11.142-0.20 ± 15.410
Physical Functioning: Change at Cycle 8 Day 1-1.33 ± 12.090-3.03 ± 13.549
Physical Functioning: Change at Cycle 9 Day 1-2.27 ± 8.765-5.06 ± 20.444
Role Functioning: Change at Cycle 2 Day 1-2.71 ± 27.442-3.11 ± 20.264
Role Functioning: Change at Cycle 3 Day 15.17 ± 27.854-4.87 ± 25.297
Role Functioning: Change at Cycle 4 Day 1-3.21 ± 25.394-6.06 ± 26.326
Role Functioning: Change at Cycle 5 Day 15.00 ± 22.361-5.33 ± 26.393
Role Functioning: Change at Cycle 6 Day 16.14 ± 21.667-3.33 ± 16.963
Role Functioning: Change at Cycle 7 Day 112.82 ± 24.677-7.07 ± 16.682
Role Functioning: Change at Cycle 8 Day 115.00 ± 25.398-4.04 ± 19.557
Role Functioning: Change at Cycle 9 Day 19.09 ± 22.808-9.77 ± 30.052
Emotional Functioning: Change at Cycle 2 Day 13.17 ± 19.6381.95 ± 20.483
Emotional Functioning: Change at Cycle 3 Day 11.15 ± 18.7301.56 ± 18.538
Emotional Functioning: Change at Cycle 4 Day 13.53 ± 22.0071.39 ± 21.277
Emotional Functioning: Change at Cycle 5 Day 15.83 ± 24.046-4.59 ± 19.622
Emotional Functioning: Change at Cycle 6 Day 17.02 ± 20.6501.04 ± 19.809
Emotional Functioning: Change at Cycle 7 Day 13.85 ± 18.199-4.63 ± 19.576
Emotional Functioning: Change at Cycle 8 Day 116.67 ± 25.0003.11 ± 19.810
Emotional Functioning: Change at Cycle 9 Day 15.30 ± 17.1892.11 ± 17.246
Cognitive Functioning: Change at Cycle 2 Day 10.78 ± 13.586-2.48 ± 26.985
Cognitive Functioning: Change at Cycle 3 Day 1-1.72 ± 16.871-4.17 ± 23.382
Cognitive Functioning: Change at Cycle 4 Day 1-0.64 ± 15.261-4.94 ± 21.385
Cognitive Functioning: Change at Cycle 5 Day 1-4.17 ± 14.178-6.46 ± 25.188
Cognitive Functioning: Change at Cycle 6 Day 1-0.88 ± 12.998-1.25 ± 19.017
Cognitive Functioning: Change at Cycle 7 Day 1-2.56 ± 11.479-5.56 ± 18.942
Cognitive Functioning: Change at Cycle 8 Day 1-6.06 ± 11.2371.52 ± 17.362
Cognitive Functioning: Change at Cycle 9 Day 1-10.61 ± 25.025-2.30 ± 23.873
Social Functioning: Change at Cycle 2 Day 10.39 ± 19.4124.50 ± 21.422
Social Functioning: Change at Cycle 3 Day 13.45 ± 16.8910.78 ± 21.088
Social Functioning: Change at Cycle 4 Day 13.85 ± 24.1791.85 ± 23.272
Social Functioning: Change at Cycle 5 Day 13.33 ± 22.6850.34 ± 23.445
Social Functioning: Change at Cycle 6 Day 110.53 ± 16.8600.00 ± 24.749
Social Functioning: Change at Cycle 7 Day 112.82 ± 22.7240.00 ± 18.162
Social Functioning: Change at Cycle 8 Day 110.61 ± 15.4072.02 ± 23.848
Social Functioning: Change at Cycle 9 Day 19.09 ± 13.670-2.30 ± 27.359
Fatigue: Change at Cycle 2 Day 15.17 ± 22.9196.44 ± 24.542
Fatigue: Change at Cycle 3 Day 11.92 ± 18.3226.58 ± 24.901
Fatigue: Change at Cycle 4 Day 1-2.56 ± 21.1547.58 ± 25.912
Fatigue: Change at Cycle 5 Day 1-5.56 ± 24.0489.67 ± 23.404
Fatigue: Change at Cycle 6 Day 1-5.85 ± 19.3767.78 ± 17.649
Fatigue: Change at Cycle 7 Day 1-1.71 ± 19.69214.14 ± 20.838
Fatigue: Change at Cycle 8 Day 1-7.78 ± 24.5959.09 ± 19.534
Fatigue: Change at Cycle 9 Day 1-1.01 ± 16.06712.64 ± 20.080
Nausea/Vomiting: Change at Cycle 2 Day 1-0.78 ± 8.0950.22 ± 12.703
Nausea/Vomiting: Change at Cycle 3 Day 10.00 ± 13.363-1.79 ± 12.884
Nausea/Vomiting: Change at Cycle 4 Day 10.00 ± 16.3300.30 ± 13.414
Nausea/Vomiting: Change at Cycle 5 Day 10.83 ± 10.0801.00 ± 13.640
Nausea/Vomiting: Change at Cycle 6 Day 1-0.88 ± 3.8241.67 ± 13.503
Nausea/Vomiting: Change at Cycle 7 Day 1-1.28 ± 14.3723.03 ± 13.472
Nausea/Vomiting: Change at Cycle 8 Day 10.00 ± 0.0000.51 ± 12.832
Nausea/Vomiting: Change at Cycle 9 Day 10.00 ± 0.000-2.30 ± 13.890
Pain: Change at Cycle 2 Day 1-2.33 ± 30.338-0.22 ± 26.351
Pain: Change at Cycle 3 Day 1-9.77 ± 22.056-1.54 ± 30.151
Pain: Change at Cycle 4 Day 10.00 ± 29.439-4.85 ± 25.795
Pain: Change at Cycle 5 Day 1-4.17 ± 25.291-4.00 ± 25.098
Pain: Change at Cycle 6 Day 1-14.04 ± 29.535-2.92 ± 24.427
Pain: Change at Cycle 7 Day 1-21.79 ± 29.174-4.04 ± 24.661
Pain: Change at Cycle 8 Day 1-13.64 ± 25.624-7.58 ± 25.716
Pain: Change at Cycle 9 Day 1-19.70 ± 27.707-5.17 ± 24.030
Dyspnoea: Change at Cycle 2 Day 12.38 ± 17.0971.33 ± 24.162
Dyspnoea: Change at Cycle 3 Day 13.57 ± 16.578-0.51 ± 23.930
Dyspnoea: Change at Cycle 4 Day 10.00 ± 16.6672.42 ± 24.724
Dyspnoea: Change at Cycle 5 Day 13.51 ± 21.9280.00 ± 28.054
Dyspnoea: Change at Cycle 6 Day 11.85 ± 13.873-1.67 ± 19.900
Dyspnoea: Change at Cycle 7 Day 12.78 ± 30.0112.02 ± 21.952
Dyspnoea: Change at Cycle 8 Day 116.67 ± 36.0042.02 ± 21.952
Dyspnoea: Change at Cycle 9 Day 16.67 ± 26.2942.30 ± 17.663
Insomnia: Change at Cycle 2 Day 1-2.33 ± 26.6220.44 ± 24.195
Insomnia: Change at Cycle 3 Day 1-6.90 ± 24.200-0.51 ± 26.016
Insomnia: Change at Cycle 4 Day 1-10.26 ± 29.468-1.82 ± 19.687
Insomnia: Change at Cycle 5 Day 1-15.00 ± 31.4841.33 ± 30.087
Insomnia: Change at Cycle 6 Day 1-17.54 ± 32.142-4.17 ± 24.093
Insomnia: Change at Cycle 7 Day 1-7.69 ± 41.1721.01 ± 28.241
Insomnia: Change at Cycle 8 Day 1-13.33 ± 54.8853.03 ± 25.500
Insomnia: Change at Cycle 9 Day 1-6.06 ± 38.9255.75 ± 25.306
Appetite loss: Change at Cycle 2 Day 14.65 ± 26.807-2.25 ± 27.215
Appetite loss: Change at Cycle 3 Day 1-2.30 ± 15.252-4.30 ± 22.163
Appetite loss: Change at Cycle 4 Day 1-1.28 ± 30.523-3.09 ± 26.117
Appetite loss: Change at Cycle 5 Day 13.33 ± 21.357-1.36 ± 30.398
Appetite loss: Change at Cycle 6 Day 1-1.75 ± 17.476-2.56 ± 29.004
Appetite loss: Change at Cycle 7 Day 1-5.13 ± 12.518-1.01 ± 30.601
Appetite loss: Change at Cycle 8 Day 1-3.33 ± 10.541-2.08 ± 31.609
Appetite loss: Change at Cycle 9 Day 1-3.03 ± 17.9791.19 ± 30.741
Constipation: Change at Cycle 2 Day 11.55 ± 19.1812.25 ± 21.603
Constipation: Change at Cycle 3 Day 10.00 ± 21.8221.06 ± 20.712
Constipation: Change at Cycle 4 Day 1-2.56 ± 18.6741.23 ± 21.440
Constipation: Change at Cycle 5 Day 15.00 ± 16.312-0.68 ± 22.037
Constipation: Change at Cycle 6 Day 10.00 ± 15.713-1.67 ± 18.413
Constipation: Change at Cycle 7 Day 15.13 ± 18.4904.04 ± 13.838
Constipation: Change at Cycle 8 Day 113.33 ± 23.307-2.02 ± 16.540
Constipation: Change at Cycle 9 Day 10.00 ± 14.9071.15 ± 22.683
Diarhoea: Change at Cycle 2 Day 13.88 ± 14.9240.45 ± 24.360
Diarhoea: Change at Cycle 3 Day 11.15 ± 14.037-1.04 ± 20.547
Diarhoea: Change at Cycle 4 Day 13.85 ± 23.715-1.85 ± 19.870
Diarhoea: Change at Cycle 5 Day 16.67 ± 20.520-0.68 ± 23.064
Diarhoea: Change at Cycle 6 Day 13.51 ± 18.904-1.67 ± 18.413
Diarhoea: Change at Cycle 7 Day 10.00 ± 13.6081.01 ± 19.516
Diarhoea: Change at Cycle 8 Day 10.00 ± 14.907-1.01 ± 19.516
Diarhoea: Change at Cycle 9 Day 10.00 ± 14.907-2.30 ± 21.696
Financial Problems: Change at Cycle 2 Day 1-3.10 ± 17.539-3.15 ± 25.385
Financial Problems: Change at Cycle 3 Day 10.00 ± 18.144-4.23 ± 24.313
Financial Problems: Change at Cycle 4 Day 1-5.13 ± 22.494-4.94 ± 23.710
Financial Problems: Change at Cycle 5 Day 10.00 ± 18.732-6.80 ± 22.546
Financial Problems: Change at Cycle 6 Day 1-1.75 ± 23.501-5.83 ± 27.099
Financial Problems: Change at Cycle 7 Day 1-2.56 ± 21.3501.01 ± 19.516
Financial Problems: Change at Cycle 8 Day 1-3.03 ± 17.9791.01 ± 19.516
Financial Problems: Change at Cycle 9 Day 1-6.06 ± 20.101-2.30 ± 23.454
Global health status/QoL: Change at Cycle 2 Day 1-3.68 ± 21.8452.55 ± 15.298
Global health status/QoL: Change at Cycle 3 Day 13.74 ± 14.362-2.55 ± 19.823
Global health status/QoL: Change at Cycle 4 Day 1-2.24 ± 14.636-0.49 ± 18.136
Global health status/QoL: Change at Cycle 5 Day 17.50 ± 14.023-1.91 ± 21.210
Global health status/QoL: Change at Cycle 6 Day 110.96 ± 11.8024.17 ± 19.447
Global health status/QoL: Change at Cycle 7 Day 116.03 ± 22.428-3.13 ± 19.715
Global health status/QoL: Change at Cycle 8 Day 19.09 ± 13.6702.15 ± 21.727
Global health status/QoL: Change at Cycle 9 Day 18.33 ± 20.412-7.14 ± 28.211
SecondaryChange From Baseline of Patient-reported Outcomes in Skindex-16 Questionnaire

Skindex-16 questionnaire contains 16 questions related to quality of life in cancer participants. It consisted of a short 16-item assessment completed by the participant, with each item rated on a 7-point Likert scale (0=never bothered to 6=always bothered). Each raw score is multiplied by 16.667 to transform all responses to a linear scale from 0 (no effect) to 100 (effect experienced all the time). Responses to the Skindex-16 are categorized into 3 subscales: symptom, emotional \& functional; their respective scores are expressed in a linear scale from 0 to 100. Symptoms scale score was an average of items 1 to 4 expressed in a linear scale from 0 to 100, Emotions scale score was an average of items 5 to 11 expressed in a linear scale from 0 to 100 and Functioning scale score was an average of items 12 to 16 expressed in a linear scale from 0 to 100. A negative change from baseline indicates an improvement in the participants condition compared to the baseline.

Time frame:
Baseline (Day 1 of Cycle 1); Day 1 of Cycles 2 to 9 (Cycles 1-5 [Each cycle of 9 weeks], Cycles 6 to 9 [Each cycle of 12 weeks])
Reported as:
Mean · Score on a Scale
Change From Baseline of Patient-reported Outcomes in Skindex-16 Questionnaire
Score on a ScaleGroup 1: Metastatic BCC (mBCC)Group 2: Unresectable Locally Advanced BCC (laBCC)
Emotions: Change at Cycle 2 Day 1-6.90 ± 24.422-8.93 ± 27.767
Emotions: Change at Cycle 3 Day 1-7.92 ± 18.033-8.60 ± 25.641
Emotions: Change at Cycle 4 Day 1-3.97 ± 17.175-11.45 ± 24.215
Emotions: Change at Cycle 5 Day 1-0.14 ± 12.835-10.25 ± 24.646
Emotions: Change at Cycle 6 Day 1-9.08 ± 22.824-19.73 ± 27.304
Emotions: Change at Cycle 7 Day 16.55 ± 17.053-13.65 ± 27.132
Emotions: Change at Cycle 8 Day 1-0.71 ± 8.478-13.97 ± 25.001
Emotions: Change at Cycle 9 Day 15.70 ± 14.711-15.08 ± 31.843
Symptoms: Change at Cycle 2 Day 10.99 ± 18.788-1.31 ± 21.607
Symptoms: Change at Cycle 3 Day 13.85 ± 16.580-0.26 ± 24.158
Symptoms: Change at Cycle 4 Day 15.30 ± 18.464-6.62 ± 23.917
Symptoms: Change at Cycle 5 Day 1-0.98 ± 15.205-4.11 ± 18.062
Symptoms: Change at Cycle 6 Day 1-1.56 ± 16.307-1.85 ± 21.419
Symptoms: Change at Cycle 7 Day 14.17 ± 23.2330.69 ± 24.518
Symptoms: Change at Cycle 8 Day 15.00 ± 17.213-2.96 ± 24.395
Symptoms: Change at Cycle 9 Day 18.33 ± 21.246-3.42 ± 24.455
Functioning: Change at Cycle 2 Day 1-3.49 ± 19.183-4.98 ± 23.650
Functioning: Change at Cycle 3 Day 1-5.00 ± 18.166-4.76 ± 20.203
Functioning: Change at Cycle 4 Day 1-8.18 ± 24.119-5.82 ± 23.275
Functioning: Change at Cycle 5 Day 1-7.06 ± 20.746-3.76 ± 16.369
Functioning: Change at Cycle 6 Day 1-12.08 ± 27.022-11.14 ± 18.113
Functioning: Change at Cycle 7 Day 1-3.89 ± 19.583-6.00 ± 15.767
Functioning: Change at Cycle 8 Day 1-7.33 ± 23.402-7.00 ± 17.926
Functioning: Change at Cycle 9 Day 1-9.39 ± 21.072-5.60 ± 20.965
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs

An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. TEAEs are defined as AEs that developed or worsened during the on-treatment period and treatment-related AEs that occur during post-treatment period. A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious TEAEs.

Time frame:
Up to 1422 days (approximately 46 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
ParticipantsGroup 1: Metastatic BCC (mBCC)Group 2: Unresectable Locally Advanced BCC (laBCC)
Participants with any TEAEs5183
Participants with any Serious TEAEs1631
SecondarySerum Concentration at Pre-infusion (Ctrough)

Ctrough of cemiplimab reported.

Time frame:
At pre-infusion on Cycle 1 Day 22 and Cycle 3 Day 1 (Each cycle of 9 weeks)
Reported as:
Mean · Milligram per Liter (mg/L)
Serum Concentration at Pre-infusion (Ctrough)
Milligram per Liter (mg/L)Group 1: Metastatic BCC (mBCC)Group 2: Unresectable Locally Advanced BCC (laBCC)
Cycle 1 Day 2228.3 ± 18.429.8 ± 12.0
Cycle 3 Day 160.6 ± 28.268.6 ± 32.8
SecondarySerum Concentration at End of Infusion (Cmax)

Cmax of cemiplimab was reported.

Time frame:
At end-of-infusion (within 10 minutes after the end of infusion) on Cycle 1 Day 1 and Cycle 3 Day 1 (Each cycle of 9 weeks)
Reported as:
Mean · mg/L
Serum Concentration at End of Infusion (Cmax)
mg/LGroup 1: Metastatic BCC (mBCC)Group 2: Unresectable Locally Advanced BCC (laBCC)
Cycle 1 Day 1103 ± 25.2104 ± 45.5
Cycle 3 Day 1160 ± 52.7192 ± 91.6
SecondaryNumber of Participants With Anti-Drug Antibody (ADA) Status

Immunogenicity was characterized by ADA responses \& titers. Responses categories: Negative - ADA negative response at all time points, regardless of missing samples; Pre-existing immunoreactivity - ADA positive response at baseline with all post first dose negative results or positive response at baseline with all post first dose ADA responses \< 9-fold over baseline titer levels; Treatment-boosted response - positive response in the assay post first dose, ≥ 9-fold over baseline titer levels, when baseline results are positive; Treatment-emergent response - ADA positive response in the cemiplimab ADA assay post first dose when baseline results = negative or missing.

Time frame:
Cycle 1: Days 1 and 43; Cycles 3 and 5: Day 1 (Each cycle of 9 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Anti-Drug Antibody (ADA) Status
ParticipantsGroup 1: Metastatic BCC (mBCC)Group 2: Unresectable Locally Advanced BCC (laBCC)
Negative ADA5074
Pre-Existing ADA22
Treatment-emergent ADA05

Adverse events

Collected over From signature of informed consent until 105 days after last dose of study drug (up to 2129 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: Metastatic BCC (mBCC)22/54 (40.7%)18/54 (33.3%)50/54 (92.6%)
Group 2: Unresectable Locally Advanced BCC (laBCC)21/84 (25%)33/84 (39.3%)76/84 (90.5%)
Most frequent serious events
Showing 10 of 82
Most frequent serious events
EventGroup 1: Metastatic BCC (mBCC)Group 2: Unresectable Locally Advanced BCC (laBCC)
Urinary tract infectionInfections and infestations1/544/84
ColitisGastrointestinal disorders2/542/84
Atrial fibrillationCardiac disorders2/540/84
AnaemiaBlood and lymphatic system disorders0/542/84
Acute kidney injuryRenal and urinary disorders0/542/84
Myocardial infarctionCardiac disorders1/542/84
Infected neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/542/84
Adrenal insufficiencyEndocrine disorders0/542/84
PneumoniaInfections and infestations1/540/84
InfectionInfections and infestations1/540/84
Most frequent other events
Showing 10 of 56
Most frequent other events
EventGroup 1: Metastatic BCC (mBCC)Group 2: Unresectable Locally Advanced BCC (laBCC)
FatigueGeneral disorders24/5425/84
DiarrhoeaGastrointestinal disorders20/5420/84
PruritusSkin and subcutaneous tissue disorders8/5420/84
ConstipationGastrointestinal disorders12/545/84
HypertensionVascular disorders12/549/84
AstheniaGeneral disorders5/5417/84
ArthralgiaMusculoskeletal and connective tissue disorders9/5416/84
Decreased appetiteMetabolism and nutrition disorders6/5414/84
NauseaGastrointestinal disorders6/5413/84
AnaemiaBlood and lymphatic system disorders6/5413/84

Baseline characteristics

The full analysis set (FAS) included all enrolled participants for each group who passed screening and were deemed to be eligible for this study.

Age, Continuous
Age, Continuous(Years)Group 1: Metastatic BCC (mBCC)Group 2: Unresectable Locally Advanced BCC (laBCC)Total
Mean63.8 ± 11.0969.1 ± 12.8467.0 ± 12.42
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: Metastatic BCC (mBCC)Group 2: Unresectable Locally Advanced BCC (laBCC)Total
Female162844
Male385694
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Group 1: Metastatic BCC (mBCC)Group 2: Unresectable Locally Advanced BCC (laBCC)Total
Race : White4757104
Race : Not Reported101
Race : Missing62733
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Group 1: Metastatic BCC (mBCC)Group 2: Unresectable Locally Advanced BCC (laBCC)Total
Ethnicity : Not Hispanic or Latino4656102
Ethnicity : Hispanic or Latino213
Ethnicity : Missing62733
08

Study locations

71 sites
  • The University of Arizona Cancer Centre at Dignity Health
    Phoenix, Arizona 85004, United States
  • Mayo Clinic Arizona - Mayo Clinic Hospital
    Phoenix, Arizona 85054, United States
  • UC San Diego Moores Cancer Center
    La Jolla, California 92093, United States
  • Stanford Medicine Outpatient Center - Stanford Dermatology Clinic-Stanford University School of Medicine
    Redwood City, California 94063-3132, United States
  • UCSF Helen Dillion Family Cancer Care Center
    San Francisco, California 94115, United States
  • University of Colorado Hospital, Anschutz Outpatient Pavilion
    Denver, Colorado 80045, United States
  • Mount Sinai Comprehensive Cancer Center
    Miami, Florida 33140, United States
  • H Lee Moffitt Cancer Center and Research Institute
    Tampa, Florida 33612, United States
  • Northwestern Medical Faculty Foundation
    Chicago, Illinois 60611, United States
  • Norton Cancer Institute
    Louisville, Kentucky 40202, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana Farber Cancer Institute (DFCI)
    Boston, Massachusetts 02215, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Atlantic Health System / Morristown Medical Center
    Morristown, New Jersey 07962, United States
  • Overlook Medical Center
    Summit, New Jersey 07901, United States
  • New York University School Of Medicine, Kaplan Comprehensive Cancer Center
    New York, New York 10016, United States
  • Mount Sinai Hospital
    New York, New York 10029, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • James Cancer Hospital and Solove Research Institute
    Columbus, Ohio 43210, United States
  • Penn State Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Clinical Research Center of the Carolinas
    Charleston, South Carolina 29407, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
  • LKH - Universitaetsklinikum Graz
    Graz, Steiermark 8036, Austria
  • Medizinische Universitaet Innsbruck, Universitaetsklinik fuer Dermatologie, Venerologie und Allergologie
    Innsbruck, 6020, Austria
  • Cliniques Universitaires Saint-Luc
    Bruxelles, 1200, Belgium
  • Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
    Leuven, 3000, Belgium
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • Odette Cancer Center-Sunnybrook Health Sciences Centre
    Toronto, Ontario M4N 3M5, Canada
  • University Health Network
    Toronto, Ontario M5G 2M9, Canada
  • London Regional Cancer Program, London Hsc
    Toronto, Ontario N6A 4L6, Canada
  • CHU de Dijon - Hopital du Bocage
    Dijon, Cedex 21000, France
  • Hopital Saint Louis
    Paris, Europe 75010, France
  • Centre Hospitalier Lyon-Sud -Hospices Civils de Lyon Groupement Hospitalier Sud
    Pierre Benite Cedex, Paris 69495, France
  • Centre Hospitalier Universitaire de Bordeaux - Groupe Hospitalier Saint-André - Hôpital Saint-André
    Bordeaux, 33000, France
  • Hopital Ambroise Pare
    Boulogne Billancourt, 92100, France
  • Centre Hospitalier Universitaire de Grenoble
    La Tronche, 38700, France
  • Hopital Huriez - CHRU de Lille
    Lille Cedex, 59037, France
  • Centre Leon-Berard (CLB)
    Lyon, 69008, France
  • CHU Hotel Dieu
    Nantes, 44093, France
  • Centre Hospitalier Universitaire de Rouen-Hopital Charles Nicolle
    Rouen cedex, 76031, France
  • Institut Claudius Regaud
    Toulouse Cedex, 31059, France
  • Institut Gustave Roussy
    Villejuif Cedex, 94805, France
  • University Hospital Frankfurt
    Frankfurt, Hessen/Germany 60590, Germany
  • Hauttumorcentrum der Charite (HTCC)-Charite Universitatsmedizin Berlin
    Berlin, C-10117, Germany
  • Elbekliniken Buxtehude
    Buxtehude, 21614, Germany
  • University Hospital Dresden
    Dresden, 01307, Germany
  • Universitaetsklinik Essen
    Essen, 45147, Germany
  • SRH Wald-Kliniken Gera GmbH
    Gera, 07548, Germany
  • Hannover Medical School
    Hannover, 30625, Germany
  • NCT Dermatoonkologie
    Heidelberg, 69120, Germany
  • University of Kiel
    Kiel, 24105, Germany
  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz
    Mainz, 55131, Germany
  • Klinik Fur Dermatologie Und Allergollogie
    Quedlinburg, 06484, Germany
  • University Hospital Tubingen
    Tübingen, 72076, Germany
  • National and Kapodistrian University of Athens - School of Health Sciences - Faculty of Medicine
    Athens, 115 27, Greece
  • National and Kapodistrian University of Athens - School of Health Sciences
    Athens, 11527, Greece
  • Andreas Sygros Hosptial-University of Athen
    Athens, 16121, Greece
  • University General Hospital of Ioannina - Dermatology and Venereology Department
    Ioánnina, 45110, Greece
  • Policlinico S.Orsola-Malpighi U.O. Dermatologia - University of Bologna
    Bologna, Bo 40138, Italy
  • Azienda Ospedaliera Spedali Civili di Brescia-Universita degli Studi Di Brescia
    Brescia, Province Of Brescia 25123, Italy
  • U.O.Dermatologia Azienda Sanitaria Firenze Universita' Firenze
    Firenze, 50132, Italy
  • University L'Aquila
    L'Aquila, 67100, Italy
  • Fondazione IRCCS Istituto Nazionale dei Tumori
    Milano, 20133, Italy
  • U.O.S.C Di Oncologia Medica E Terapie Innovative
    Napoli, 80131, Italy
  • Catholic University of the S.Heart
    Roma, 168, Italy
  • Catalan Institute of Oncology Badalona
    Badalona, 08916, Spain
  • Hospital Clinic I Provincialde Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitario de Torrejon
    Madrid, 28850, Spain
  • Hospital Universitario Virgen Macarena
    Sevilla, 41009, Spain
  • University Hospital Zurich Usz
    Zürich, 8091, Switzerland
09

References and documents

Publications

  • Stratigos AJ, Sekulic A, Peris K, Bechter O, Prey S, Kaatz M, Lewis KD, Basset-Seguin N, Chang ALS, Dalle S, Orland AF, Licitra L, Robert C, Ulrich C, Hauschild A, Migden MR, Dummer R, Li S, Yoo SY, Mohan K, Coates E, Jankovic V, Fiaschi N, Okoye E, Bassukas ID, Loquai C, De Giorgi V, Eroglu Z, Gutzmer R, Ulrich J, Puig S, Seebach F, Thurston G, Weinreich DM, Yancopoulos GD, Lowy I, Bowler T, Fury MG. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol. 2021 Jun;22(6):848-857. doi: 10.1016/S1470-2045(21)00126-1. Epub 2021 May 14. PubMed 34000246 ↗
  • Li R, Lee G, Huang M, El-Sherief A. Rare basal cell metastasis of a basal-squamous skin collision tumour to the lung and axillary lymph node. BMJ Case Rep. 2019 Oct 3;12(10):e231487. doi: 10.1136/bcr-2019-231487. PubMed 31585957 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in May 2021, 46 months.

Results were first posted in Jul 2022, 1 year 2 months after primary completion.

Of 43 phase 2 interventional studies under Carcinoma, Basal Cell, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 67. This study's 46 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2017
First posted
Apr 28, 2017
StartActual
Jun 29, 2017
Primary completionActual
May 20, 2021
CompletionActual
Apr 27, 2023
Results first posted
Jul 26, 2022
Last update
Apr 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03132636
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Apr 28, 2017
Start date
Jun 29, 2017
Primary completion
May 20, 2021
Completion
Apr 27, 2023
Results posted
Jul 26, 2022
Last update
Apr 8, 2025

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cemiplimab

Start the discussion